Anticancer Drug Development, Getting Out from Bottleneck

Abstract

Drug development as a sensitive thermometer represents the scientific and technical power-engines for any countries. As a result, drug manufacture (highly competitive area) is pillar industry for small-range of developed countries and highest medical expenditures worldwide. Nonetheless, new anticancer drug discovery, development and manufacture were entering into bottleneck stage two decades ago. A declining successful rate of phase II and phase III anticancer drug evaluations is the grimmest situation for most leading anticancer drug developers worldwide. Profit is down every years. Owing to all these kinds of undesired factors, anticancer drug developments manufacturing and licensing have been highly risky over the past two decades. This article addresses key factors affecting anticancer drug developments and possible roadmaps for drug screening model and routine updating in all relevant countries are especially speculated.

Design, in silico studies, synthesis, and in vitro anticancer assessment of new naphthylidene isoxazolidinedione derivatives

“…1,2 Considering the cancer epidemiology and its notoriously convoluted biology, it is an alarming condition as only scanty actives reach the clinical stage. 3,4 Thus, continuous efforts are ongoing to explore various new therapeutics to successfully combat the disease. Among these discoveries, the development of synthetic chemical entities has been considered a source for the discovery of anticancer small molecules.…”

“…Though currently available therapies are effective for the treatment of early stages of cancer, patient survival remains limited due to various factors such as toxicity, drug resistance, etc 1,2 . Considering the cancer epidemiology and its notoriously convoluted biology, it is an alarming condition as only scanty actives reach the clinical stage 3,4 . Thus, continuous efforts are ongoing to explore various new therapeutics to successfully combat the disease.…”